Guangzhou, China-based Bio-Thera has filed a biologics license application (BLA) with the FDA for the approval of bevacizumab biosimilar candidate BAT1706.
The FDA has accepted a biologics license application (BLA) for the review of BAT1706, a proposed biosimilar to bevacizumab, referencing Avastin. If approved, the Bio-Thera Solutions biosimilar candidate would become the third bevacizumab biosimilar on the US market. The others are Mvasi and Zirabev.
In the United States, Mvasi (Amgen) was launched in July 2019 and Zirabev (Pfizer) in January 2020. By June, 2020, these biosimilars had achieved a 40% share of the US market for bevacizumab, according to Amgen.
Zirabev and Mvasi were launched at average sales prices (ASPs) 19% and 12% below the ASP of Avastin, respectively. By the end of the second quarter of 2020, they had contributed to a 2% decline in the ASP of Avastin.
Bio-Thera is a Guangzhou, China-based company with offices in Beijing and Cambridge, Massachusetts. The FDA has established a November 27, 2021, decision date for the application.
Bio-Thera is seeking approval for use of BAT1706 in the treatment of metastatic colorectal cancer in combination with fluorouracil-based chemotherapy, first-line treatment of nonsquamous non–small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma in combination with interferon alfa, and persistent, recurrent, or metastatic cervical cancer.
The company said it has also filed for regulatory approval in China and the European Union, thereby “demonstrating Bio-Thera’s commitment to developing BAT1706 to global standards so that BAT1706 can be made available to the global cancer patient community.”
Bio-Thera said the BLA submission is based on positive data from preclinical comparison studies, pharmacokinetic studies, and an international, multicenter, phase 3 clinical comparison study. These provided evidence that BAT1706 is highly similar to the reference product in terms of clinical efficacy, safety, and immunogenicity, the company said.
The company has commercialized 1 biosimilar so far, to adalimumab, a rheumatologic and gastrointestinal therapy. The product is Qletli, which references AbbVie’s Humira and is marketed in China. The company is also developing biosimilar versions of tocilizumab, golimumab, ustekinumab, and secukinumab, which are all immunosuppressants and indicated for such conditions as arthritis and plaque psoriasis. The company is also developing a mepolizumab biosimilar, an anti-inflamatory for the treatment of asthma, eosinophilic granulomatosis, and hyperosinophilic syndrome.
In December 2020, Bio-Thera announced it had formed a partnership with Brazil-based Biomm for the commercialization of BAT1706 in Brazil. Biomm will file the regulatory application.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.